Rigontec
Sep 07, 2017
CAR-T Phase I trials; ContraVir Announces; Merck acquired; Excision BioTherapeutics bags $10M
Two ongoing CAR-T Phase I trials of Cellectis drug candidate has been put on hold by FDA after a patient’s death FDA has put two CAR-T trials on hold following a patient’s death, less than a week after the first ever CAR-T was approved by the US regulatory agency. The patient (78) was suffering from r...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
